Building things in America again carries a price tag that makes even defense budgets look modest. McKinsey Global Institute’s latest research estimates the US would need roughly $2 trillion in capital expenditure just to replace imports of strategically vulnerable manufactured goods, a sum equivalent to about 6% of GDP.

To put that in perspective, that’s roughly two full years of the current US defense budget. And it only covers building new factories and production lines. Workforce training, infrastructure upgrades, and energy supply expansions would all cost extra.

The scale of the problem

The US imports approximately $3 trillion worth of manufactured goods each year. McKinsey’s report, titled “Ramping up manufacturing in America?”, found that about 25% of those imports qualify as what the firm calls “Achilles’ heels.” These are products that depend on concentrated supply chains and carry meaningful geopolitical risk.

Replacing those exposed imports would require roughly doubling current domestic production capacity across most categories. McKinsey introduced a metric called the “ramp-up factor” to illustrate the gap. For most goods, that factor sits around 2x.

For certain product categories, the numbers get genuinely alarming. Some active pharmaceutical ingredients would require production increases exceeding 5x current output. AI servers would need capacity scaled up by more than 10x.

Reshoring momentum versus reality

The report acknowledges some positive signals. Tariff-driven supply chain shifts in 2025 nudged companies toward reconsidering domestic production.

But McKinsey’s assessment is blunt: current efforts are woefully inadequate compared to the scale of what’s actually needed. The funding itself, while staggering in absolute terms, is described in the report as relatively manageable compared to operational hurdles around workforce, energy, and infrastructure.

What this means for investors

A $2 trillion capital expenditure wave, even if it materializes over a decade or more, would reshape investment flows across multiple sectors. Advanced manufacturing technology companies are the obvious beneficiaries. The ramp-up factor for AI servers alone, at more than 10x, signals massive potential demand for domestic semiconductor and data center infrastructure.

The pharmaceutical angle deserves particular attention. With some active ingredients requiring 5x or greater production increases, the healthcare supply chain is arguably the most vulnerable sector McKinsey identified.

The risk for investors is that political will fades before the capital actually flows. McKinsey’s report quantifies the gap in stark terms: the companies best positioned are those solving the operational bottlenecks around workforce, energy, and infrastructure, not just the financing ones.